Description
Introduction To Celdaz 500 Mg Injection:
Celdaz 500 Mg Injection is a prescription anticancer medicine containing Dacarbazine 500 mg, used to treat malignant melanoma and Hodgkin’s lymphoma. It works by damaging the DNA of cancer cells, helping slow or stop their growth. This medicine is administered intravenously by a qualified healthcare professional under strict medical supervision.
It may also be used to treat other conditions as determined by your doctor. The dose and frequency depend on what you’re being treated for and may change over time. Take it exactly as your doctor has instructed — misuse or overdose can cause severe side effects. Benefits may take a few weeks or months to appear, so don’t stop taking it unless your doctor advises.
Uses Of Celdaz 500 Mg Injection:
- Harmful melanoma
- Hodgkin’s infection
Benefits Of Celdaz 500 Mg Injection:
1. In Malignant melanoma
Harmful melanoma is a kind of skin disease that creates in melanocytes, the phones that produce the colour called melanin. Melanin is the shade that gives the skin its tone. Threatening melanoma is the most lethal and forceful sort of skin disease. Celdaz 500 mg Injection adheres to the hereditary code, called DNA, of the disease cells and kills them. It additionally forestalls their development and further spread. This assists with treating the disease.
2. In Hodgkin’s sickness
Hodgkin’s sickness is a kind of lymphoma, which is a blood disease that begins in the lymphatic framework. The lymphatic framework assists the invulnerable framework with disposing of waste and battle diseases. Celdaz 500 mg Injection kills or stops the development of malignant growth cells and furthermore forestalls the increase of disease cells. Adhere to your physician’s guidelines cautiously.
Mechanism Of Action Of Celdaz 500 Mg Injection:
Celdaz 500 mg Injection is an enemy of malignant growth drug. It works by harming the hereditary material (DNA and RNA) of the disease cells. This stops their development and increase.

Reviews
There are no reviews yet.